3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
117
Neoplasms
42
Carcinoma, Neuroendocrine
34
Carcinoma, Non-Small-Cell Lung
32
Carcinoid Tumor
30
Multiple Endocrine Neoplasia Type 1
28
Melanoma
27
Breast Neoplasms
27
Colorectal Neoplasms
25
Small Cell Lung Carcinoma
24
Pancreatic Neoplasms
22
Carcinoma, Renal Cell
22
Gastro-enteropancreatic neuroendocrine tumor
21
Neoplasm Metastasis
20
Lung Neoplasms
19
Sarcoma
18
Carcinoma, Hepatocellular
18
Adrenocortical Carcinoma
18
Stomach Neoplasms
17
Uterine Cervical Neoplasms
15
Thyroid Neoplasms
15
Thyroid Carcinoma, Anaplastic
15
Thyroid Cancer, Papillary
15
Pheochromocytoma
15
Ovarian Neoplasms
15
Carcinoma
14
Prostatic Neoplasms
13
Paraganglioma
13
Head and Neck Neoplasms
13
Colonic Neoplasms
13
Interventions
lanreotide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Flushing
×
Endocrine
×
Clear all
NCT00774930
2022-10-14
ELECT
Ipsen
Phase 3
Completed
115 enrolled
17 charts